2-(氨基甲基)庚酸 | 56439-53-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(氨基甲基)庚酸
• 英文名称: D,L-2-Aminomethylheptansaeure
• 英文别名: 2-(Aminomethyl)-heptansaeure；Heptanoic acid, 2-(aminomethyl)-；2-(aminomethyl)heptanoic acid
• CAS: 56439-53-3
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: CYJQXMOJSMLOGT-UHFFFAOYSA-N

物化性质

• 沸点：
  273.2±23.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-methyleneheptanoic acid 在 ammonium hydroxide 作用下， 生成 2-(氨基甲基)庚酸
  参考文献：
  名称：

  有关抗生素肌动蛋白的研究。第一部分。肌动蛋白的组成。具有抗生素活性的天然异羟肟酸

  摘要：

  抗生素肌动蛋白已显示具有与源自L-脯氨醇，L-缬氨酸，D-戊基琥珀酸和羟胺的残基相关的新型假肽结构（XII）。

  DOI：

  10.1039/p19750000819

文献信息

• Studies concerning the antibiotic actinonin. Part IV. Synthesis of structural analogues of actinonin by the mixed anhydride method
  作者：Barbara J. Broughton、Peter J. Warren、Kenneth R. H. Wooldridge、Derek E. Wright、W. David Ollis、Ronald J. Wood

  DOI：10.1039/p19750000842

  日期：——

  The reaction between alkylsuccinic anhydrides (III) and O-benzylhydroxylamine yields the acids (VI). These acids (VI) may be coupled with amino-amides (II) by the mixed anhydride procedure, giving a mixture of the racemates (VIII) and (IX). Hydrogenolysis of the O-benzylhydroxamic acids (VIII) and (IX) yields structural analogues [(X) and (XI)] of the natural antibiotic actinonin (I).

  烷基琥珀酸酐（III）和O-苄基羟胺之间的反应产生酸（VI）。这些酸（VI）可以通过混合酸酐法与氨基酰胺（II）偶联，得到外消旋物（VIII）和（IX）的混合物。O-苄基异羟肟酸（VIII）和（IX）的氢解产生天然抗生素肌动蛋白（I）的结构类似物[（X）和（XI）] 。
• Studies concerning the antibiotic actinonin. Part III. Synthesis of structural analogues of actinonin by the anhydride–imide method
  作者：John P. Devlin、W. David Ollis、John E. Thorpe、Ronald J. Wood、Barbara J. Broughton、Peter J. Warren、Kenneth R. H. Wooldridge、Derek E. Wright

  DOI：10.1039/p19750000830

  日期：——

  A synthetic route, associated with a high degree of stereoselectivity, has been developed for the synthesis of structural analogues (XIII) of actinonin (I). The anhydride–imide method involves the sequence (IIIb)+(V)→[(VI)+(VII)]→(XI)→(XIII). (±)-Amino-amides (IIIb) yielded the (±)-hydroxamic acids with the relative configuration (XIII) and L-amino-amides (X) yielded single enantiomers with the absolute

  已经开发了具有高度立体选择性的合成路线，用于合成肌动蛋白（I）的结构类似物（XIII）。酸酐-酰亚胺法涉及序列（IIIb）+（V）→ [（VI）+（VII）] →（XI）→（XIII）。（±）-氨基酰胺（IIIb）产生具有相对构型（XIII）的（±）-异羟肟酸，并且L-氨基酰胺（X）产生具有绝对构型（XIII）的单一对映体。
• SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20190233409A1

  公开（公告）日：2019-08-01

  The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof wherein R 1 is C 1 -C 5 alkyl; R 2 , is independently hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2,3, or 4; Ar is unsubstituted phenyl or substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle one or, with two nitrogen atoms in the heterocycle; excluding the compounds of the formulas A1-A4 The invention relates to the novel chemical compounds, methods for their preparation and use as antagonists of 5-HT 6 receptors, simultaneously regulating homeostasis of calcium ions in cells. The invention relates to the novel annelated azaheterocycles—2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, to methods for their preparation, to pharmaceutical compositions, including these compounds as active substances, and to methods of treatment and profylaxis of various diseases.

  本发明涉及公式1.2的化合物，或其药学上可接受的盐或水合物，其中R1为C1-C5烷基；R2独立地为氢、卤素、C1-C3烷基、CF3、O 或OCH3；i为1、2、3或4；Ar为未取代的苯基或取代的苯基，取代基为卤素、C1-C6烷基、C1-C6烷氧基、取代氨基或三氟甲基；或Ar为取代或未取代的6元芳杂环之一，其中异杂环中含有两个氮原子；但不包括A1-A4式的化合物。本发明涉及新的化学化合物、其制备方法以及作为5-HT6受体拮抗剂的用途，同时调节细胞内钙离子的稳态。本发明涉及新的螺合的氮杂环-2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物，以及其制备方法、包括这些化合物作为活性物质的制药组合物，以及各种疾病的治疗和预防方法。
• [EN] USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS<br/>[FR] UTILISATION DE CERTAINS DILUANTS POUR L'ELABORATION D'ACIDES BISPHOSPHONIQUES
  申请人：TEVA PHARMA

  公开号：WO2003097655A1

  公开（公告）日：2003-11-27

  Provided is a novel method of making bisphosphonic acids, e.g. risedronic acid, including the step of combining a carboxylic acid, phoshorous acid, and a halophosphorous compound in the presence of a diluent that is an aromatic hydrocarbon or a silicone fluid. When the diluent is an aromatic hydrocarbon, a inert support or ortho-phosphoric acid codiluent is advantageously included.

  提供了一种制备双膦酸的新方法，例如利塞酸，包括在芳香烃或硅流体存在的稀释剂中将羧酸，磷酸和卤磷化合物结合的步骤。当稀释剂是芳香烃时，优选地包括惰性支撑物或邻-磷酸共溶剂。
• SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Alla Chem, LLC

  公开号：US20130217703A1

  公开（公告）日：2013-08-22

  The present invention relates to a method of antagonizing a 5-HT 6 serotonin receptor and simultaneously regulating Ca +2 ion homeostasis in a cell, comprising administering to the cell a compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: R 1 is a C 1 -C 5 alkyl; R 2 i is independently hydrogen, halogen, a C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle; and W is an ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to new compounds selected from the group of compounds of the general formula 1, method for their preparation, pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease, or obesity in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1 according to claim 1 , or a pharmaceutically acceptable salt thereof.

  本发明涉及一种拮抗5-HT6 5-羟色胺受体和同时调节细胞内Ca+2离子稳态的方法，包括向细胞中投与式1的化合物或其药学上可接受的盐，其中：R1是C1-C5烷基；R2独立地是氢、卤素、C1-C3烷基、CF3、O 或OCH3；i为1、2、3或4；Ar是未取代的苯基或取代的苯基，其被卤素、C1-C6烷基、C1-C6烷氧基、取代的氨基团或三氟甲基取代；或Ar是带有一个或两个氮原子的取代或未取代的6元芳香杂环；W是乙烯基—CH2— —、乙烯基—CH═CH—或乙炔基—C≡C—。本发明还涉及从式1的化合物组中选择的新化合物、其制备方法、制备药物组合物的方法以及治疗认知障碍或神经退行性疾病或肥胖症的方法，包括向需要治疗的受体中投与式1的化合物或其药学上可接受的盐的有效剂量。